Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating restated by equities research analysts at Mizuho in a report released on Monday. They currently have a $70.00 price target on the stock. Mizuho’s price objective would indicate a potential upside of 44.03% from the stock’s current price.

A number of other analysts also recently issued reports on the stock. Canaccord Genuity restated a “buy” rating on shares of Aerie Pharmaceuticals in a report on Friday, September 22nd. Stifel Nicolaus lifted their price target on shares of Aerie Pharmaceuticals from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Tuesday, July 4th. BidaskClub upgraded Aerie Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Zacks Investment Research cut Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Finally, HC Wainwright set a $69.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $66.36.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded up 0.51% during midday trading on Monday, hitting $48.85. The company had a trading volume of 600,500 shares. The company has a 50-day moving average of $54.83 and a 200-day moving average of $50.04. The company’s market capitalization is $1.78 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $61.30.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. Analysts predict that Aerie Pharmaceuticals will post ($2.59) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Aerie Pharmaceuticals, Inc. (AERI) Stock Rating Reaffirmed by Mizuho” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at

Hedge funds have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in Aerie Pharmaceuticals during the 1st quarter worth about $107,000. Ameritas Investment Partners Inc. purchased a new position in Aerie Pharmaceuticals during the 1st quarter valued at about $108,000. BNP Paribas Arbitrage SA boosted its holdings in Aerie Pharmaceuticals by 2,711.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after acquiring an additional 3,579 shares during the period. BlueCrest Capital Management Ltd purchased a new position in Aerie Pharmaceuticals during the 1st quarter valued at about $202,000. Finally, Amalgamated Bank acquired a new position in Aerie Pharmaceuticals in the 2nd quarter valued at about $204,000. Hedge funds and other institutional investors own 94.64% of the company’s stock.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Stock Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.